© Reuters. FILE PHOTO: A bridge is embellished with the brand of a Bayer AG, a German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Ratta/File Picture
FRANKFURT (Reuters) -The Bayer (OTC:) investor Union Funding criticized Bayer’s chair for a scarcity of engagement, reminiscent of exploring a spin-off of the corporate’s client well being division, in response to an interview in WirtschaftsWoche.
Bayer is dealing with calls for from activist investor Bluebell Capital Companions to interrupt up, with a sale of the corporate’s client well being unit and, at a later stage, for a separation of Bayer’s prescription drugs and agriculture companies.
Bayer Chair Norbert Winkeljohann “does search dialogue with traders, however he ought to have initiated extra,” Markus Manns, portfolio supervisor at Union Funding, advised WirtschaftsWoche.
“It might positively have been a matter for the supervisory board to assist provoke a spin-off of Client Well being,” Manns added. He famous that chairs at opponents are way more engaged in creating worth for shareholders.
Winkeljohann didn’t instantly reply to a request for remark.
A spokesperson for Bayer declined to touch upon Union Funding’s place. “However typically talking we’re all the time open to a constructive dialogue with our stakeholders,” the spokesperson mentioned.
